First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Journal of Clinical Oncology · 10.06.2024 · 42 (17) · 2012-2020
DOI: 10.1200/jco.23.01601 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2024. Verfasst von Yelena Y Janjigian und 25 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Stomach Neoplasms, Nivolumab. Die Arbeit wurde bisher 260-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report 3-year efficacy and safety results from the phase III CheckMate 649 trial. Patients with previously untreated advanced or metastatic gastroesophageal adenocarcinoma were randomly assigned to nivolumab plus chemotherapy or chemotherapy. Primary end points were overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) in patients whose tumors expressed PD-L1 combined positive score (CPS) ≥5. With 36.2-month minimum follow-up, for patients with PD-L1 CPS ≥5, the OS hazard ratio (HR) for nivolumab plus chemotherapy versus chemotherapy was 0.70 (95% CI, 0.61 to 0.81); 21% versus 10% of patients were alive at 36 months, respectively; the PFS HR was 0.70 (95% CI, 0.60 to 0.81); 36-month PFS rates were 13% versus 8%, respectively. The objective response rate (ORR) per BICR was 60% (95% CI, 55 to 65) with nivolumab plus chemotherapy versus 45% (95% CI, 40 to 50) with chemotherapy; median duration of response was 9.6 months (95% CI, 8.2 to 12.4) versus 7.0 months (95% CI, 5.6 to 7.9), respectively. Nivolumab plus chemotherapy also continued to show improvement in OS, PFS, and ORR versus chemotherapy in the overall population. Adding nivolumab to chemotherapy maintained clinically meaningful long-term survival benefit versus chemotherapy alone, with an acceptable safety profile, supporting the continued use of nivolumab plus chemotherapy as standard first-line treatment for advanced gastroesophageal adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Johannes-Gutenberg University Clinic, Mainz, Germany.
- Peking University Cancer Hospital & Institute, Beijing, China.
- Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile.
- Fundación Arturo López Pérez, Providencia, Chile.
ORCID-Profile: Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M Cleary, Michalis Karamouzis, Mustapha Tehfe, Thomas Zander, Ruben Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, Kohei Shitara
Förderung
- NCI NIH HHS
Zitieren
APA
Janjigian, Y. Y., Ajani, J. A., Moehler, M., Shen, L., Garrido, M., Gallardo, C., Wyrwicz, L., Yamaguchi, K., Cleary, J. M., Elimova, E., Karamouzis, M., Bruges, R., Skoczylas, T., Bragagnoli, A., Liu, T., Tehfe, M., Zander, T., Kowalyszyn, R., Pazo-Cid, R., …, & Shitara, K. (2024). First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of Clinical Oncology, 42(17), 2012-2020. https://doi.org/10.1200/jco.23.01601
Vancouver
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of Clinical Oncology. 2024;42(17):2012-2020. doi:10.1200/jco.23.01601
BibTeX
@article{Janjigian2024,
author = {Janjigian, Yelena Y and Ajani, Jaffer A and Moehler, Markus and Shen, Lin and Garrido, Marcelo and Gallardo, Carlos and Wyrwicz, Lucjan and Yamaguchi, Kensei and Cleary, James M and Elimova, Elena and Karamouzis, Michalis and Bruges, Ricardo and Skoczylas, Tomasz and Bragagnoli, Arinilda and Liu, Tianshi and Tehfe, Mustapha and Zander, Thomas and Kowalyszyn, Ruben and Pazo-Cid, Roberto and Schenker, Michael and Feeny, Kynan and Wang, Rui and Lei, Ming and Chen, Clara and Nathani, Raheel and Shitara, Kohei},
title = {First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {17},
pages = {2012--2020},
doi = {10.1200/jco.23.01601}
}
EUVIMED